Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 29, 2011

Expedeon, Protein Discovery Ink Merger Deal

  • Expedeon and Protein Discovery have decided to come together to create a supplier of products for protein research. The new Expedeon created under the merger agreement will have a portfolio of protein analysis and purification products.

    Protein Discovery, founded in 2001, develops and commercializes sample preparation products for protein analysis by mass spectrometry. Its flagship product is the Gelfree® 8100 Fractionation System. It partitions complex protein mixtures into user-selectable, liquid-phase molecular weight fractions. The company also has consumables like the FASP™ Protein Digestion kits and PPS Silent® Surfactant.

    Expedeon develops tools and reagents for protein discovery and analysis. Its products include solutions for protein separation, quantitation, visualization, purification, protection, and refolding. Its portfolio includes RunBlue® electrophoresis precast gels, InstantBlue® protein stain, and Nvoy™ protein stabilization products. It has offices in Cambridge, U.K., and San Diego, CA, and products are sold through a network of partners around the globe.

    The new entity will remain headquartered in Cambridge, U.K. "This transaction represents an important step toward our strategic goal of becoming a premier, global provider of innovative product solutions for protein analysis," says Heikki Lanckriet, founder and CEO of Expedeon, who will be CEO of the new company.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »